RxDoctor Payments Data

Erik Daniels, PA

Medical · Beckley, WVNPI 1508013053

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,963 of the $5,556 with a category attached, or 89.3%. 16 manufacturers reported payments, led by UCB, Inc. at 27.3% of the total. 2025 is the largest year on record at $2,139, more than ten times the $45 reported in 2021. Among medical clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,556in general payments, 2019–2025

Across 444 payments — averaging $12.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$295
  • Regeneron Healthcare Solutions, Inc.$218
  • E.r. Squibb & Sons, L.L.C.$208
  • plus $659 from 10 others

What the payments were for

  • Food & beverage$4,96389%
  • Education$59211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,556 in reported general payments places this provider in the 90th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$208,377
Medicare patients
391
Services billed
3,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab29$350,334
Dupixent PenDupilumab62$247,094
OlumiantBaricitinib20$129,906
Taltz AutoinjectorIxekizumab17$111,610
RinvoqUpadacitinib13$82,112
HumiraAdalimumab12$73,425
Dupixent SyringeDupilumab12$44,515
Tacrolimus100$19,598
SantylCollagenase Clostridium Hist.17$7,828
Clobetasol Propionate169$7,532
Triamcinolone Acetonide323$5,942
Ketoconazole342$5,128
Metronidazole68$3,197
Tretinoin18$2,245
Clindamycin Phosphate32$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$1,414$155,53625 claims
Lilly USA, LLCOlumiant$62$129,90620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 233 medical providers in West Virginia.

Other medical in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →